Source link : https://newshealth.biz/health-news/pbm-private-labeling-boosts-biosimilars-raises-concerns/
Nearly 2 years after entering the market, adalimumab biosimilars are finally seeing traction. CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx, which are pharmacy benefit managers (PBMs) that collectively control about 80% of all prescriptions in the United States, are now pivoting away from Humira and preferring biosimilars on their formularies. But rather […]
The post PBM Private Labeling Boosts Biosimilars, Raises Concerns first appeared on News Health.
Author : News Health
Publish date : 2025-04-03 13:31:00
Copyright for syndicated content belongs to the linked Source.